Overview
Kidney Week Conference Coverage
Highlights in FSGS and IgAN
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this brief video, Dr. Edgar Lerma explores data on focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) coming out of ASN 2022. Dr. Lerma discusses current challenges in diagnosing and managing these kidney diseases, and how emerging data and therapies may impact current clinical practice.
This activity is intended for nephrologists, primary care, internal medicine, and other clinicians interested in treating patients with focal segmental glomerulosclerosis and/or IgA nephropathy.
The treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) is challenging due to disease heterogeneity and a lack of therapeutic approaches. A number of therapies, including some with novel mechanisms of action, are under investigation for treating these progressive kidney diseases. Therefore, clinicians need up-to-date understanding of these therapies and available efficacy and safety data to incorporate them into treatment paradigms once they are available.
Upon completion of this activity, participants will be able to:
• Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
• Outline emerging therapies and pathways for FSGS and IgAN
• Interpret clinical trial data and endpoints from clinical trials with emerging therapies
• Discuss challenges in the care and pharmacologic management of patients with FSGS or IgAN
• Outline emerging therapies and pathways for FSGS and IgAN
• Interpret clinical trial data and endpoints from clinical trials with emerging therapies
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Travere Therapeutics, Inc.
Edgar V. Lerma, MD, FASN, FNKF, FPSH (Hon)
Clinical Professor of Medicine
Section of Nephrology
University of Illinois at Chicago
Chicago, IL
Clinical Professor of Medicine
Section of Nephrology
University of Illinois at Chicago
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Edgar V. Lerma, MD, FASN, FNKF, FPSH (Hon)
Advisor or Review Panel Member: Akebia, AstraZeneca, Bayer, GlaxoSmithKline, Otsuka, Travere, Vifor
Honorarium: Akebia, AstraZeneca, Bayer, Glaxo Smith Kline, Otsuka, Travere, Vifor
Speaker Bureau: Bayer, Glaxo Smith Kline
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Agents (Atrasentan, sparsentan, and DMX-200) under investigation for FSGS and IgAN.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 15 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 50% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
